Case Report

Zygomatic Bone Metastasis as an Initial Presentation of Hepatocellular Carcinoma

Nada Tomanovic PhD1, Aleksandar Krstic MD2, Dimitrije Brasanac PhD3, Milovan Dimitrijevic PhD2, Tatjana Terzic PhD4, Ivan Boricic PhD5

Abstract

Hepatocellular carcinoma is the most common type of primary liver cancer. It metastasizes via blood or through lymphatic dissemination, most commonly to the lungs, abdominal lymph nodes, and bones. Metastases to the bones of the head and neck region, however, are extremely uncommon. A 70-year-old male was presented with a mass in the left zygomatic region. After the incisional biopsy, the histopathologic and immunohistochemical analysis confirmed a metastasis of hepatocellular carcinoma. An abdominal computerized tomography (CT) scan revealed a large primary tumor in the right liver lobe. To the best of our knowledge, this is the second case of an isolated zygomatic metastasis as an initial presentation of hepatocellular carcinoma. We also reviewed the literature regarding clinical and histopathologic characteristics of hepatocellular carcinoma that produced metastases to the zygomatic bone and the maxilla.

Keywords: Hepatocellular carcinoma, immunohistochemistry, maxilla, metastasis, zygomatic bone


Introduction

Hepatocellular carcinoma (HCC) metastasizes via blood or lymphatic dissemination, most commonly to the lungs (55%), abdominal lymph nodes (41%), or bones (28%).1 Metastases to osseous structures in the head and neck are extremely uncommon, particularly to the maxilla and zygomatic bone.2,3–13 Here, we report a rare patient who had HCC with isolated zygomatic metastasis as the initial presentation of the disease.

Case Report

A 70-year-old male patient was presented to the clinic with a complaint of a painless, soft mass in the left zygomatic region that had been slowly enlarging during the previous six months. The patient had no other signs or symptoms of the malignant disease. On the facial computerized tomography (CT) scan there was a soft-tissue-density mass emanating from the left zygomatic region. The patient had no other signs or symptoms of the malignant disease. The patient had been slowly enlarging during the previous six months. The patient had no other signs or symptoms of the malignant disease.

The skin, that was approximately 60 mm in the largest diameter (Figure 3). The patient had been treated only with symptomatic therapy and died six months after the diagnosis had been established.

Discussion

HCC is a primary liver cancer that is clinically silent for most of its course, and the majority of patients present with an advanced disease that has little chance for effective treatment. In the study by Pawarode, extrahepatic metastases were seen in 18 % of 157 patients with untreated HCC.1 In those uncommon cases when HCC produces metastases to the head and neck region, they are usually seen in the oral cavity, mandible, or maxilla. In a paper by Huang, et al. 77 cases of metastatic HCC in the head and neck region were cited.2 Regarding metastases of HCC in the maxillary and zygomatic region, only 13 cases have been reported so far (Table 1), two of them involving the zygomatic bone.3,4 Majority of patients with metastases of HCC in the maxillary region were males, with a mean age of 59.6 years (range: 42 to 75 years).2–12 Only one case of a female patient (78 years old) has been reported.10 Our patient was also a 70-year-old male, similar to other published cases. Dimensions of maxillary metastases (ranging from 12 mm to 39 mm) were stated only in four reports, including two cases with the zygomatic bone affection (30 mm and 39 mm).3,4,10,12 Metastasis in our case was larger, 60 mm in diameter, perhaps related to the six-month duration of visible metastatic growth before...
### Table 1. Characteristics of the Published Cases Reporting Metastasis of Hepatocellular Carcinoma in the Maxilla and Zygomatic Bone

<table>
<thead>
<tr>
<th>No.</th>
<th>Gender</th>
<th>Age</th>
<th>Affected bone</th>
<th>Size of metastasis</th>
<th>Size of primary tumor</th>
<th>Duration of metastasis before diagnosis</th>
<th>IHC Presentation</th>
<th>Therapy</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>52</td>
<td>Zygomatic, temporal skull, subcutaneous tissue</td>
<td>30 mm</td>
<td>Not stated</td>
<td>3 months</td>
<td>Initial</td>
<td>Partial resection-surgery for metastasis</td>
<td>Death after 3 months</td>
<td>Reichbach (1970)</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>62</td>
<td>Maxilla</td>
<td>12x15 mm</td>
<td>Not stated</td>
<td>1 month</td>
<td>Initial</td>
<td>Not initial - had HCC for 2 years</td>
<td>Death during hospitalization</td>
<td>Morita (1978)</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>78</td>
<td>Maxilla</td>
<td>20 mm</td>
<td>Not stated</td>
<td>1 month</td>
<td>Initial</td>
<td>Surgery for metastasis</td>
<td>Not stated</td>
<td>Kenzaki (1979)</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>59</td>
<td>Maxilla</td>
<td>39 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>Not initial - had HCC for 4 years</td>
<td>Not stated</td>
<td>Nonradial (1980)</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>67</td>
<td>Maxillary sinus</td>
<td>30 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>Partial resection-surgery for metastasis</td>
<td>Initial Partial resection-surgery for metastasis</td>
<td>Death after 3 months</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>64</td>
<td>Maxillary sinus</td>
<td>30 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>Surgery for metastasis</td>
<td>Initial Surgery for metastasis</td>
<td>Not stated</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>59</td>
<td>Maxilla</td>
<td>60 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>Not initial - had HCC for 4 years</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>71</td>
<td>Maxilla</td>
<td>39 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>Partial resection-surgery for metastasis</td>
<td>Initial Partial resection-surgery for metastasis</td>
<td>Death after 6 months</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>70</td>
<td>Maxilla, maxillary sinus, retrobulbar space</td>
<td>20 mm and 30 mm</td>
<td>Not stated</td>
<td>2 months</td>
<td>Initial</td>
<td>HepPar1+, Vimentin-, TTF-1-, CK7-, CD34-, CD10+, CD56-, pCEA+</td>
<td>Chemotherapy and biliary transposition for primary tumor</td>
<td>Alve after 6 months</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>75</td>
<td>Maxilla, maxillary sinus, retrobulbar space</td>
<td>60 mm</td>
<td>Not stated</td>
<td>3 months</td>
<td>Initial</td>
<td>HepPar1+, Vimentin-, TTF-1-, CK7-, CD34-, CD10+, CD56-, pCEA+</td>
<td>Chemotherapy and biliary transposition for primary tumor</td>
<td>Death after 3 months</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>64</td>
<td>Maxilla, maxillary sinus, retrobulbar space</td>
<td>60 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>HepPar1+, Vimentin-, TTF-1-, CK7-, CD34-, CD10+, CD56-, pCEA+</td>
<td>Chemotherapy and biliary transposition for primary tumor</td>
<td>Death after 3 months</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>52</td>
<td>Maxilla</td>
<td>60 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>HepPar1+, Vimentin-, TTF-1-, CK7-, CD34-, CD10+, CD56-, pCEA+</td>
<td>Chemotherapy and biliary transposition for primary tumor</td>
<td>Death after 6 months</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>42</td>
<td>Maxilla, maxillary sinus, retrobulbar space</td>
<td>60 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Initial</td>
<td>HepPar1+, Vimentin-, TTF-1-, CK7-, CD34-, CD10+, CD56-, pCEA+</td>
<td>Chemotherapy and biliary transposition for primary tumor</td>
<td>Death after 6 months</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>71</td>
<td>Zygomatic bone, maxillary sinus</td>
<td>60 mm</td>
<td>Not stated</td>
<td>6 months</td>
<td>Current case</td>
<td>HepPar1+, Vimentin-, TTF-1-, CK7-, CD34-, CD10+, CD56-, pCEA+</td>
<td>Chemotherapy and biliary transposition for primary tumor</td>
<td>Current case</td>
</tr>
</tbody>
</table>

**IHC:** immunohistochemistry; **HCC:** hepatocellular carcinoma; **AFP:** alpha-feto-protein; **HepPar1:** human hepatocyte paraffin antibody-1; **CK20:** cytokeratin 20; **PIVKA II:** protein-induced vitamin K absence; **mCEA:** monoclonal carcinoembryonic antigen; **pCEA:** polyclonal carcinoembryonic antigen; **TTF-1:** thyroid transcription factor-1; **RCC Ag:** renal cell carcinoma antigen; **mCEA:** monoclonal carcinoembryonic antigen; **pCEA:** polyclonal carcinoembryonic antigen.
the diagnosis. Duration of metastasis before the correct diagnosis has been stated in eight published papers, ranging from one month up to six months.\textsuperscript{2,3,4,6,7,9,10,12} Dimensions of primary liver tumor has been declared only in three of the published papers, ranging from 20 mm to 60 mm,\textsuperscript{3,5,10} much smaller than the primary tumor in our patient (114 mm). In most cases, the diagnosis has been

**Figure 1.** Facial CT scan shows soft-tissue-density mass in the left zygomatic region.

**Figure 2.** Biopsy findings of the zygomatic bone metastasis: A) large, polygonal tumor cells in a trabecular pattern with mitotic figures in the center (arrow); B) HepPar 1 immunohistochemical stain shows strong and diffuse positivity in the cytoplasm of tumor cells (A - hematoxillin and eosin (H\&E), original magnification x 400; B- streptavidin-biotin, original magnification x 400).

**Figure 3.** Abdominal CT scan with primary tumor in the right liver lobe.
made using the routine hematoxillin and eosin (H&E) sections; immunohistochemistry was performed only in cases reported by Kolarevic, et al.\(^2\) and Satake, et al.\(^6\) In the head and neck region, a number of other metastatic tumors, notably from the breast, kidney, and adrenal glands may histopathologically mimic the trabecular, liver-like pattern of HCC; hence, immunohistochemistry might be very useful, especially in those cases with initial presentation of HCC as a metastasis.\(^{4,5,9}\) In eight cases, the patients already knew the primary liver tumor\(^2\),\(^3\),\(^6\),\(^7\),\(^9\),\(^11\),\(^12\) and in one report it was not stated whether the manifestation of HCC metastasis was an initial presentation of malignant liver tumor.\(^13\)

To explain the absence of lung involvement (as in our case), it has been suggested that HCC could disseminate into plexus of vertebral veins (Batson’s plexus) which represent a pathway up and down the spine that does not involve the heart or the lungs. This venous plexus provides an explanation of ‘aberrant’ metastatic patterns and absence of lung involvement.\(^14\) In published reports, surgical therapy (eight cases) was applied for metastases in the maxillary region.\(^3\),\(^5\),\(^10\),\(^12\) Radiation therapy was applied for metastases in the maxillary region in two cases,\(^5\),\(^11\) and the combination of surgical and radiation therapy for metastasis in one case.\(^1\) In two papers the outcome was not stated,\(^6\),\(^13\) but in eight cases there was a lethal outcome one to six months after the diagnosis of bone metastasis\(^3\),\(^4\),\(^5\),\(^7\),\(^8\),\(^10\)–\(^12\) and one patient died during hospitalization.\(^9\) One patient who was treated with liver transplantation for primary tumor and surgery for metastasis was reported to be alive after 12 months.\(^3\) Huang, et al. reported two cases with sinonasal metastases of HCC who were treated with chemotherapy (sorafenib) and biotherapy (Avastin), and with six cases there was a lethal outcome one to six months after the diagnosis had been established.\(^9\)

To the best of our knowledge, this is the third well documented report of a zygomatic HCC metastasis, and the second one with an isolated metastasis in the zygomatic bone as an initial presentation of HCC. Immunohistochemistry with HepPar 1, combined with pCEA and CD10 antibodies is a useful adjunct that can focus further imaging studies and facilitate diagnosis in such patients.

**Acknowledgment**

*This paper was supported, in part, by the Serbian Ministry of Science (Project No. 175026).*

**Conflicts of interest:** None.

**References**


